Prime Medicine, Inc., a biotechnology company focused on developing genetic medicines, reported a net loss of $201.1 million for the year ended December 31, 2025, compared to a net loss of $195.9 million for the previous year. The company has accumulated a deficit of $888.4 million as of the end of 2025. Revenue generation from product sales is not expected in the foreseeable future, with current revenues primarily derived from research collaboration and license agreements. The company's financial performance is significantly influenced by research and development activities, which are expected to increase as programs advance into clinical trials.
The increase in research and development expenses, totaling $5.3 million, was primarily driven by a $11.0 million increase in facility-related expenses due to the expansion of laboratory space, a $6.9 million increase in license and intellectual property fees, and a $1.8 million increase in professional and consultant fees. These increases were partially offset by a $9.3 million decrease in personnel expenses resulting from a workforce reduction and a $6.2 million decrease in research costs due to the deprioritization of the CGD program. General and administrative expenses increased by $2.2 million, mainly due to a $7.0 million increase in professional and consultant fees, offset by decreases in personnel and facility-related expenses.
Operationally, Prime Medicine is focused on advancing its in vivo liver franchise, specifically programs targeting Wilson Disease and AATD, with IND and/or CTA filings expected in 2026. The company is also progressing its Cystic Fibrosis program with support from the Cystic Fibrosis Foundation and its Prime Edited CAR-T program in partnership with Bristol-Myers Squibb. As of December 31, 2025, the company had 146 full-time employees, with a significant portion dedicated to research and development.
Prime Medicine's financial outlook includes expectations of continued operating losses and reliance on additional funding through equity offerings, debt financings, and collaborations. As of December 31, 2025, the company's cash, cash equivalents, and investments totaled $177.7 million, excluding restricted cash. The company believes these funds will be sufficient to support operations into 2027. However, the company acknowledges substantial doubt about its ability to continue as a going concern beyond that timeframe without securing additional funding.
About Prime Medicine, Inc.
Prime Medicine is a biotechnology company specializing in developing precise, one-time gene editing therapies using its proprietary Prime Editing technology. Focused on genetic diseases like chronic granulomatous disease and Wilson’s disease, it aims to correct mutations across various tissues and cell types. The company leverages innovative delivery platforms and strategic partnerships to create durable, potentially curative treatments with broad therapeutic applications.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.